NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=96722&from=3 CLASS PERIOD: March 7, 2 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MacroGenics To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in MacroGenics between March 7, 2024 to May 9, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Aug. 21, 2024 /PRNewswire ...

SAN DIEGO, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired MacroGenics, Inc. (NASDAQ: MGNX) common stock between March 7, 2024 and May 9, 2024. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. For more information, submit a form, email ...

RADNOR, Pa., Aug. 17, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. (“MacroGenics”) (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the “Class Period” The lead plaintiff deadline is September 24, 2024. CONTAC ...

文章核心观点 - 生物技术公司MacroGenics面临重大压力,其前列腺癌药物候选药物Vobra Duo的临床试验数据令人失望,严重影响了该资产的价值主张[3][4] - 公司还面临集体诉讼,指控其就Vobra Duo的安全性做出了误导性陈述,导致投资者遭受重大损失,公司市值已缩水三分之二[5] - 著名诉讼律所Hagens Berman正在调查公司是否存在证券法违规行为,重点关注其关于Vobra Duo试验的公开声明[6][7] 根据相关目录分别进行总结 公司概况 - MacroGenics是一家生物技术公司,主要从事前列腺癌药物Vobra Duo的研发[3] 负面事件 - Vobra Duo的临床试验数据令人失望,严重影响了该资产的价值主张[3][4] - 公司面临集体诉讼,指控其就Vobra Duo的安全性做出了误导性陈述,导致投资者遭受重大损失[5] - 公司市值已缩水三分之二[5] 监管调查 - 著名诉讼律所Hagens Berman正在调查公司是否存在证券法违规行为,重点关注其关于Vobra Duo试验的公开声明[6][7] - 公司面临潜在的监管处罚风险 其他 - 公司鼓励投资者提交损失信息,并呼吁潜在的内部人士提供线索,以获得SEC举报人奖励[9]

NEW YORK, Aug. 15, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX).Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=95548&from=4CLASS PERIOD: March 7, 2024 to M ...

NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the “Class Period”), of the important September 24, 2024 lead plaintiff deadline. SO WHAT: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a cont ...

RADNOR, Pa., Aug. 14, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024.CONTACT KES ...

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=95113&from=3 CLASS PERIOD: March 7, 2 ...

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of MacroGenics, Inc. (NASDAQ: MGNX) stock or sellers of MacroGenics puts between March 7, 2024 and May 9, 2024, inclusive (the “Class Period”), have until September 24, 2024 to seek appointment as lead plaintiff of the MacroGenics class action lawsuit. Captioned Crain v. MacroGenics, Inc., No. 24-cv-02184 (D. Md.), the MacroGenics class action lawsuit charges MacroGenics as well as MacroGenics’ Chief Exec ...